« Mêmes chances » campaign : Quebeckers ask the Minister of Health and ... Canada NewsWire (press release) Remember that this treatment, in combination with rituximab, is accessible to the majority of other Canadian provinces and prolongs survival without disease progression for patients with indolent non-Hodgkin Lymphoma (iNHL) from 31.2 months to 69.5 ... |
